Global Blood Therapeutics, Inc. (GBT) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues [Abstract]
Product sales, net	194.7	123.8	2.1	9.0
Product sales, net growth	57.3%	5773.0%	-76.5%
Costs and operating expenses:
Cost of sales	3.3	2.0	0.0
Research and development	212.1	155.1	174.6	131.3	87.8	62.2	36.7	16.3
Selling, general and administrative	267.0	210.9	117.1	51.4	31.4
Total costs and operating expenses	482.4	734.5	574.9	182.7	119.2
Loss from operations	-287.7	-243.2	-281.3	-182.7	-119.2	-83.1	-46.4	-20.5
Operating margin	-147.7%	-196.4%	-13343.6%	-2038.6%

Other income (expense):
Interest income	0.7	5.8	15.6	9.0
Interest expense	-15.5	-9.8	-0.9	-0.3
Other income (expense), net	-14.9	-4.4	14.5	8.5	4.8	1.3	0.1	0.0
Total other income (expense,), net	-14.9	-4.4	14.5	8.5	-0.3
Loss before income taxes	-302.6	-247.6	-266.8
Provision for income taxes	0.5		0.0
Net loss	-303.1	-247.6	-266.8	-174.2	-117.0	-82.5	-46.4	-20.8

Other comprehensive loss:
Cumulative translation adjustment	0.3

Total other comprehensive expense, net
Comprehensive loss	-303.3	-248.0	-266.0	-173.9	-117.2	-82.6	-46.4	-20.8

Basic net loss per common share	($4.81)	($4.04)	($4.57)	($3.41)	($2.76)	($2.48)	($3.95)	($14.20)
Diluted net loss per common share	($4.81)	($4.04)	($4.57)	($3.41)	($2.76)	($2.48)	($3.95)	($14.20)

Weighted-average number of shares used in computing basic net loss per common share	63.0	61.3	58.3	51.2	42.4	33.2	12.8	1.7